I-Mab (IMAB)

3.6000 -0.1000 (-2.70%) At close: 01:00PM EST

I-Mab

New Bund Center
55th – 56th Floor 555 West Haiyang Road Pudong District
Shanghai 200124
China
86 21 6057 8000
https://www.i-mabbiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 378

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jingwu Zhang Zang M.D., Ph.D.	Founder & Chairman	N/A	N/A	1956
Dr. Andrew X. Zhu M.D., Ph.D.	Member of Scientific Advisory Board, Pres, Acting CEO & Director	N/A	N/A	1960
Dr. Jerry Wang	Co-Founder & Chief Scientific Officer	N/A	N/A	N/A
Mr. Richard L. Yeh M.B.A.	Interim CFO, COO & Director	N/A	N/A	1968
Mr. Tianyi Zhang	VP of Investor Relations	N/A	N/A	N/A
Mr. Cheng Li	Chief Legal Officer	N/A	N/A	1984
Ms. Gigi Qi Feng	Chief Communications Officer	N/A	N/A	1981
Dr. Weiming Tang Ph.D.	Exec. VP of Global Bus. Devel. & Chief Bus. Officer	N/A	N/A	1966
Dr. Fernando J. Salle´s Ph.D.	Sr. VP and Head of U.S. & EU Bus. Devel.	N/A	N/A	N/A
Mr. Ivan Yifei Zhu	Chief Commercial Officer	N/A	N/A	1969

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Corporate Governance

I-Mab’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.